Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation and expansion study of SHR-1501 alone or with BCG intravesical instillation or SHR-1316 in non-muscle-invasive bladder cancer
CTR20221344Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-1501 in bladder cancer (4 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity, Recommended phase 2 dose and 2 more. Started Nov 2022; status: active.
02
Drugs
SHR-1501
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20221344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221344.